Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension

Quarck Rozenn, Wynants Marijke, Verbeken Erik, Meyns Bart, Delcroix Marion

Source: Eur Respir J 2015; 46: 431-443
Journal Issue: August
Disease area: Pulmonary vascular diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Quarck Rozenn, Wynants Marijke, Verbeken Erik, Meyns Bart, Delcroix Marion. Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. Eur Respir J 2015; 46: 431-443

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
How does inflammation contribute to pulmonary hypertension?
Source: Eur Respir J, 51 (1) 1702403; 10.1183/13993003.02403-2017
Year: 2018



Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature
Source: Eur Respir J 2014; 44: 1275-1288
Year: 2014



Inflammatory cell accumulation in pulmonary arteries is associated with systemic inflammation in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease
Year: 2010


Crucial role of thrombin-activated fibrinolysis inhibitor in the pathogenesis of chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015

The ADAMTS13–VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J, 53 (3) 1801805; 10.1183/13993003.01805-2018
Year: 2019



Regulation of inflammation process in chronic thromboembolic pulmonary hypertension: a potential role of platelet-activating factor-acetylhydrolase
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006


Inflammation in chronic thromboembolic pulmonary hypertension: accomplice or bystander in altered angiogenesis?
Source: Eur Respir J 2015; 46: 303-306
Year: 2015


Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology
Source: Eur Respir Rev 2009; 19: 59-63
Year: 2010



The Role of Inflammation in promoting pulmonary hypertension in idiopatchi and connective tissue disease-associated PAH
Source: Research Seminar 2008 - The Pulmonary Circulation: Scleroderma-Related Pulmonary Arterial Hypertension
Year: 2008


Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension?
Source: Eur Respir J 2014; 44: 842-845
Year: 2014


Reduced pulmonary vascular response to hypoxia is associated with endothelial dysfunction in chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: Suppl. 33, 173s
Year: 2001

Novel hypoxia system to assess endothelial dysfunction in chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension
Year: 2021


Systemic inflammation in chronic obstructive pulmonary disease in patients with pulmonary hypertension
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010

Circulating microRNA signature and its novel involvement in pathogenesis of chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012

ERS statement on chronic thromboembolic pulmonary hypertension
Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension
Year: 2021


Involvement of the pulmonary micro-vasculature in chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012


Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011

Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010

Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis
Source: Eur Respir J 2012; 40: 93-100
Year: 2012